Inventiva (NASDAQ:IVA - Free Report) had its price objective cut by HC Wainwright from $22.00 to $14.00 in a report issued on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.
Separately, Stifel Nicolaus lowered their target price on shares of Inventiva from $25.00 to $20.00 and set a buy rating on the stock in a research report on Thursday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Inventiva has a consensus rating of Buy and an average target price of $16.50.
Read Our Latest Stock Analysis on IVA
Inventiva Stock Down 19.2 %
Inventiva stock traded down $0.42 during midday trading on Thursday, reaching $1.75. The company's stock had a trading volume of 55,263 shares, compared to its average volume of 20,974. The business has a 50-day simple moving average of $2.28 and a 200-day simple moving average of $2.99. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $4.75.
Hedge Funds Weigh In On Inventiva
An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC purchased a new position in Inventiva S.A. (NASDAQ:IVA - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 10,490 shares of the company's stock, valued at approximately $38,000. Institutional investors own 19.06% of the company's stock.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
See Also
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
